Dr Reddy's Laboratories has moved higher by 2% at Rs 1,712 on launching Quetiapine fumarate tablets in the US market from March 27.
“The company has launched Quetiapine fumarate tablets, a bioequivalent generic version of SEROQUEL tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA),” Dr Reddy’s Laboratories said in a filing to the stock exchanges.
The SEROQUEL brand had U.S. sales of approximately $4.6 billion for the most recent twelve months ending December 2011 according to IMS Health.
Dr. Reddy's Quetiapine fumarate tablets in 25 mg and 50 mg are available in 100 and 500 count bottle sizes, 100 mg, 200 mg and 400 mg are available in 100 count bottle sizes and 300 mg is available in 60 count bottle sizes, it added.
A combined around 9,000 shares have changed hands on the counter so far on the NSE and BSE.
